Randialic acid B, a triterpenoid compound, is a formyl peptide receptor 1 (FPR1) antagonist. Randialic acid B blocks FPR1 in human neutrophils and attenuates psoriasis-like inflammation in vivo^[1].

Randialic acid B (0.1-3 μM; for 5 min) selectively inhibits reactive oxygen species production, elastase release, and CD11b expression in human neutrophils activated by FPR1. Randialic acid B inhibits the binding of N-formyl peptide to FPR1 in human neutrophils, neutrophil-like THP-1 cells, and hFPR1-transfected HEK293 cells, indicating FPR1 antagonism^[1].
Randialic acid B acts competitively for its binding to the FPR1 receptor. The FPR1-downstream signaling such as Ca²⁺ mobilisation and activation of Akt and MAPKs is also competitively inhibited^[1].
Randialic acid B shows significant cell-protective effects against H2O2-induced H9c2 cardiomyocyte injury^[2].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

Randialic acid B (10 mg/kg; i.v.; every other day; for 5 days) significantly reduces Imiquimod-induced psoriasis-like symptom, including epidermal hyperplasia, desquamation with scaling, neutrophil skin infiltration, and transepidermal water loss^[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

454.68

C₃₀H₄₆O₃

14021-14-8

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Michal Korinek, et al. Randialic acid B and tomentosolic acid block formyl peptide receptor 1 in human neutrophils and attenuate psoriasis-like inflammation in vivo. Biochem Pharmacol. 2021 Aug;190:114596.

  [2]. Shan-Shan Li, et al. Three new triterpenoids isolated from the aerial parts of Ilex cornuta and protective effects against H 2 O 2-induced myocardial cell injury. Chin J Nat Med. 2017 Feb;15(2):115-120.